Related Experiment Video
Updated: Jun 29, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas
M A Scheper1, R Chaisuparat, N G Nikitakis
1Department of Diagnostic Sciences and Pathology, University of Maryland, Baltimore, MD 21201, USA. mscheper@umaryland.edu
Objectives:
Recently, an allelic loss of phosphatase and tensin homologue (PTEN) was shown to occur in ameloblastomas. In carcinogenesis, loss of PTEN allows for overactivity of the phosphatidylinositol-3-kinase/protein kinase B (PI3K / AKT) pathway inducing an upregulation of mammalian-target of rapamycin (mTOR) and its downstream effector ribosomal-subunit-6 kinase (S6K); allowing for uncontrolled cell proliferation, apoptosis inhibition and cell cycle deregulation.
Methods:
Thirty ameloblastomas and five dental follicles were studied, looking at the immunohistochemical expression of total PTEN and AKT, as well as their phosphorylated (p) active forms, and the downstream effector and indicator of mTOR activity p70 ribosomal-subunit-6 kinase (pS6K). Also assessed was the expression of extracellular-signal-regulated kinase (ERK), which cross talks with AKT.
Results:
Total PTEN was absent in 33.3% of ameloblastomas, while its stabilized, phosphorylated(ser380 / thr382 / thr383) form was absent in 83.3% of tumors. In contrast, AKT was expressed in 83.3% of ameloblastomas, showing high expression of the p-thr(308)AKT and p-ser(473) AKT forms in 93.3% and 56.6% of cases, respectively. Further, the mTOR activated pS6K(ser240 / 244) was detected in 86.7% of ameloblastomas, while ERK was overexpressed in 70.0% of the cases.
Conclusion:
Immunohistochemical analysis of aberrant signaling in the PI3K/AKT/mTOR pathway in ameloblastomas may represent a valuable tool for elucidating pathogenesis, aggressiveness and selecting optimal therapeutics.
Insights
Loss of phosphatase and tensin homologue (PTEN) is frequent in ameloblastomas, leading to overactive PI3K/AKT/mTOR signaling. This pathway dysregulation drives uncontrolled cell proliferation and survival, impacting tumor development.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ameloblastomas exhibit allelic loss of phosphatase and tensin homologue (PTEN).
- PTEN loss activates the phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway, upregulating mammalian-target of rapamycin (mTOR).
- This aberrant signaling promotes uncontrolled cell proliferation, inhibits apoptosis, and deregulates the cell cycle.
Purpose of the Study:
- To investigate the immunohistochemical expression of PTEN, AKT, and downstream signaling molecules in ameloblastomas.
- To assess the role of the PI3K/AKT/mTOR pathway in ameloblastoma pathogenesis.
Main Methods:
- Immunohistochemical analysis of 30 ameloblastomas and 5 dental follicles.
- Assessed expression of total and phosphorylated PTEN and AKT.
- Evaluated phosphorylated ribosomal-subunit-6 kinase (pS6K) as an indicator of mTOR activity and extracellular-signal-regulated kinase (ERK).
Main Results:
- PTEN was absent in 33.3% and its active form in 83.3% of ameloblastomas.
- High expression of active AKT forms (p-thr308 and p-ser473) was observed in 93.3% and 56.6% of tumors, respectively.
- Activated mTOR signaling (pS6K) was detected in 86.7% of ameloblastomas, with ERK overexpression in 70.0%.
Conclusions:
- Aberrant signaling in the PI3K/AKT/mTOR pathway is a common feature of ameloblastomas.
- Immunohistochemical analysis of this pathway can aid in understanding ameloblastoma pathogenesis and aggressiveness.
- Targeting the PI3K/AKT/mTOR pathway may offer therapeutic strategies for ameloblastomas.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
